Chemotherapy in patients with metastatic or relapsed germ-cell tumours

Abstract 

The optimal treatment in patients with poor prognosis germ-cell tumours (GCT), according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification, and in patients with refractory or relapsed disease after cisplatin-based chemotherapy is controversial. As the majority of patients will suffer systemic relapses, chemotherapy is the mainstay of treatment. However, the question of whether or not to use conventional-dose or high-dose chemotherapy (HDCT) in these patients arises. Prognostic factors have recently been recognised to aid in this decision. However, reliable data on chemotherapy as primary treatment in poor prognosis patients and as the first-salvage attempt in patients with relapsed or refractory GCT are lacking. This report reviews the recent developments in first-line and salvage HDCT strategies and discusses the role of predictive factors for treatment outcome.

No full text is available. To read the body of this article, please view the PDF online.

• f1 Correspondence to: O. Rick, Klinik für Innere Medizin m.S. Hämatologie/Onkologie, Campus Mitte, Charité, Schumann Straße 20/21, 10117 Berlin, Germany, Tel. ++49-30-450 513268; Fax: ++49-30-450 513966; E-mail:oliver.rick@charite.de